Eiger BioPharmaceuticals Inc. (EIGR) Sank To A 4-Month Low On Study Results

Eiger BioPharmaceuticals Inc. (EIGR) announced Tuesday morning that its Phase 2 study of ubenimex in pulmonary arterial hypertension demonstrated no improvement for both the primary endpoint of pulmonary vascular resistance and the secondary endpoint of 6-minute walk distance.

from RTT - Before the Bell http://ift.tt/2riuJzn
via IFTTT